Atherosclerosis Drugs Market Report 2026

Atherosclerosis Drugs Market Overview

• Atherosclerosis Drugs market size has reached to $50.91 billion in 2025 • Expected to grow to $61.19 billion in 2030 at a compound annual growth rate (CAGR) of 3.9% • Growth Driver: Atherosclerosis Drugs Rise With The Surge In Cardiovascular Diseases • Market Trend: Atherosclerosis Drugs Market Adopts Anti-Inflammatory Strategies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atherosclerosis Drugs Market?

Atherosclerosis drugs refer to medications used to manage and treat atherosclerosis, a condition characterized by the buildup of plaque in the arteries. The goals of atherosclerosis drug treatment are to reduce plaque formation, slow its progression, and manage risk factors that contribute to atherosclerosis. The main types of atherosclerosis drugs are anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and others. Antiplatelet medications refer to drugs that inhibit the formation of blood clots by interfering with the aggregation of platelets, which are small cell fragments in the blood. It is consumed through oral and injectable routes of administration, and mainly distributed through hospital pharmacies, Online Pharmacies, retail pharmacies, and others.

What Is The Atherosclerosis Drugs Market Growth Forecast?

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $61.19 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to expansion of precision medicine in cardiovascular treatment, increased adoption of digital health monitoring tools, rising demand for combination therapies, growth in geriatric population, innovation in novel anti-atherosclerosis drug classes. Major trends in the forecast period include personalized atherosclerosis therapy, combination drug formulations, minimally invasive treatment support, preventive cardiovascular healthcare, patient adherence & digital monitoring.

What Is The Driver Of The Atherosclerosis Drugs Market?

The prevalence of cardiovascular diseases is expected to propel the growth of the atherosclerosis drug market going forward. Cardiovascular diseases refer to all the diseases that can affect the heart and blood vessels, and atherosclerosis refers to the buildup of fats, cholesterol, and other substances on the artery walls of a person. Atherosclerosis is a condition characterized by the buildup of plaque inside the arteries that causes cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs are used to treat cardiovascular diseases by reducing the risk of complications and managing underlying conditions such as increased cholesterol levels and blood clot formation. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the prevalence of cardiovascular diseases will drive the atherosclerosis drug industry.

Key Players In The Global Atherosclerosis Drugs Market

Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.

Global Atherosclerosis Drugs Market Trends and Insights

Major companies operating in the atherosclerosis drugs market are developing new products, such as anti-inflammatory drugs, to increase their profitability in the market. Atherosclerosis anti-inflammatory drugs refer to medications designed to mitigate inflammation associated with atherosclerosis, a condition characterized by the buildup of plaque in arteries. For instance, in June 2023, AGEPHA Pharma, a Europe-based manufacturer of medical products, launched LODOCO. LODOCO (colchicine, 0.5 mg tablet) has been granted approval by the U.S. FDA as the pioneering anti-inflammatory atheroprotective cardiovascular treatment. The drug has proven efficacy in lowering the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. LODOCO addresses residual inflammation, a key factor in atherosclerotic cardiovascular disease (ASCVD). This drug has been approved for use either alone or in conjunction with cholesterol-lowering medications, represents a notable breakthrough in cardiovascular care.

What Are Latest Mergers And Acquisitions In The Atherosclerosis Drugs Market?

In April 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical company, acquired Amryt Pharma plc for approximately $1.25 billion. Through this acquisition, Chiesi Farmaceutici S.p.A. aims to expand its rare disease portfolio, access Amryt's pipeline of development candidates, and enter the US market. Amryt Pharma plc is an Ireland-based pharmaceutical company that develops atherosclerosis drugs for treatments for rare diseases such as atherosclerosis, generalized lipodystrophies, and others.

What Defines the Atherosclerosis Drugs Market?

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atherosclerosis Drugs Market Report 2026?

The atherosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.